title: Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma.
abstract: A total of 23 patients with metastatic sarcomas were treated with continuous oral trofosfamide, an alkylating agent structurally related to cyclophosphamide and ifosfamide. In all, 12 of the patients were chemotherapy-naive. Doses were escalated every 3rd week until the development of leukopenia of WHO grade 2. The treatment was well tolerated and produced little subjective toxicity. Leukopenia was the dose-limiting toxicity. The daily dose that produced grade 2 leukopenia was 200-250 mg in 65% of the patients. Three patients responded, all of whom had been treated with trofosfamide as first-line treatment.
authors.affiliation: Department of Radiotherapy and Oncology, University of Helsinki, Finland.
authors.forename: C
authors.initials: C
authors.lastname: Blomqvist
authors.forename: T
authors.initials: T
authors.lastname: Wiklund
authors.forename: M
authors.initials: M
authors.lastname: Pajunen
authors.forename: M
authors.initials: M
authors.lastname: Virolainen
authors.forename: I
authors.initials: I
authors.lastname: Elomaa
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D018572:Disease-Free Survival; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D003520:Cyclophosphamide; C003726:trofosfamide